gp130/IL6ST 蛋白, Human (HEK293)

Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family^[1]. gp130 inhibits the cell growth and migration^[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity^[4][5]. gp130/IL6ST Protein, Human (HEK293) is a recombinant protein consisting of 596 amino acids (M23-I618) and is produced by HEK293 cells.

糖蛋白130（gp130）mRNA在人体内广泛表达，在隐静脉、心包、卵巢、网膜脂肪组织、腹膜、脾淋巴结和三叉神经节中表达水平最高。与胎儿器官相比，成人器官中gp130的表达显着增加。此外，与正常组织相比，gp130 在多种类型的癌症中高表达^[3]。
人 gp130 蛋白的氨基酸序列与小鼠和大鼠 gp130 蛋白的同源性较低。
当自分泌或旁分泌细胞因子诱导 gp130 和 α 受体亚基二聚化形成受体复合物时，gp130 信号传导启动，导致下游信号级联的激活，例如 JAK/STAT、PI3K/Akt、和 Ras/Raf/Mek/Erk1/2MAPK 通路。JAK/Stat3通路的激活诱导其靶基因表达，导致细胞生长、增殖（cyclin D、CDC25 A、c-Myc、survivin）、生存（survivin、Bcl-2、Bcl-X_L)、血管生成 (VEGF) 和细胞迁移（MMP-2、MMP-7 和 MMP-9）^[3]。gp130 是一种 IL-6 拮抗剂，具有抗肿瘤、抗炎和抗伤害活性^[4]。gp130 降低 IL-6 诱导的 STAT3 磷酸化，并降低 IL-6 诱导的 Ki67^[5] 增加。

gp130 (human) (-1.14 µg/mL; 24 h) inhibits the cell growth in a dose-dependent manner and induces apoptosis in HepG2 cells^[5].
gp130 (human) (-2 ng/mL; 48 h) significantly decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67 in HepG2 cells^[5].

gp130 (human) (5 µg/mL; i.p., 2 µL; every third day for 12 days) shows antinociceptive effect in antigen-induced arthritis rats^[4].
gp130 (human) (2 µg/mL; i.a.; 5 µL; every third day for 12 days) shows antinociceptive effect in antigen-induced arthritis rats^[4].
gp130 (human) (1.14 µg/kg; i.v.; every 3 days for 35 days) suppresses tumor growth in NOD/SCID mice with HepG2 cells injection^[5].

Human

HEK293

Tag Free

P40189-1/NP_002175.2 (E23-I618)

3572  [NCBI]

Approximately 94.9 kDa

Greater than 90% as determined by reducing SDS-PAGE.

溶液.

Supplied as a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

N/A.

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping with dry ice.

• [1]. Cao Y, et al. Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer. Sci Rep. 2016 Dec 5;6:38364.  [Content Brief]

  [2]. Nogueira-Silva C, et al. The role of glycoprotein 130 family of cytokines in fetal rat lung development. PLoS One. 2013 Jun 24;8(6):e67607.  [Content Brief]

  [3]. Xu S, et al. gp130: a promising drug target for cancer therapy. Expert Opin Ther Targets. 2013 Nov;17(11):1303-28.  [Content Brief]

  [4]. Boettger MK, et al. Differential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis. Arthritis Res Ther. 2010;12(4):R140.  [Content Brief]

  [5]. Hong J, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep. 2016 Apr 15;6:24397.  [Content Brief]